#USA #Mount Pleasant #Paradigm Therapeutics #SD-101 #Zorblesia

Paradigm Therapeutics Secures Nomination for the 2026 Prix Galien USA

Paradigm Therapeutics, Inc., a biopharmaceutical company dedicated to innovating treatments for rare diseases, has made headlines by being nominated for the esteemed Prix Galien USA 2026 award in the "Best Start-Up" category for its groundbreaking topical treatment, SD-101 (Zorblesia™). This marks the second consecutive year that Paradigm has reached this prestigious recognition, following its nomination in 2025.

The Prix Galien USA is widely regarded as the Nobel Prize of biopharmaceutical research, celebrating outstanding scientific innovations that address significant unmet medical needs. Managed by the Galien Foundation, this award acknowledges promising initiatives that have clinical relevance and the potential to significantly enhance human health. The awards ceremony will be held on October 29, 2026, at the American Museum of Natural History in New York City.

Dr. Robert Ryan, CEO of Paradigm Therapeutics, expressed enthusiasm about the nomination: "This recognition is a testament to the significant progress we have made in treating epidermolysis bullosa (EB) and illustrates the strength of our scientific research, the effectiveness of our team, and our unwavering commitment to developing a therapy aimed at addressing the skin surface needs of patients suffering from all three main subtypes of EB."

Epidermolysis bullosa is a rare genetic condition characterized by extreme skin fragility, manifesting in debilitating blisters and wounds often from birth. Currently, no approved therapies exist to treat skin lesions across all subtypes of EB. The SD-101 treatment represents a pioneering approach to manage this life-altering disease.

In clinical trials, which included Phase II and Phase III studies, SD-101 was evaluated in 217 patients affected by the three primary subtypes of EB: simplex, dystrophic, and junctional. Results have indicated that the cream shows significant benefits in treating skin lesions and wounds while maintaining a favorable long-term safety profile. Notably, the formulation is stable at room temperature and easy to apply, making it a viable option for both pediatric and adult patients.

"The need for new treatment options for the entire skin surface of EB patients is considerable," stated Dr. Ryan. "We are committed to progressing the development of SD-101 and advancing towards regulatory approval, actively collaborating with potential partners to bring this therapy to patients worldwide as quickly as possible."

SD-101 (Zorblesia™), recognized by the FDA with breakthrough therapy designation, also carries orphan drug status alongside a rare pediatric disease designation. These recognitions pave the way for a priority review voucher (PRV) upon regulatory approval, further ensuring that this innovative treatment can reach its intended audience promptly.

As a private clinical-stage company, Paradigm Therapeutics is wholly focused on addressing critical medical needs through its advanced therapies for epidermolysis bullosa. With SD-101 nearing potential market entry, its success could revolutionize the standard of care for patients grappling with this chronic and often disfiguring condition.

For those wanting to learn about the transformative therapies being developed for EB, Paradigm Therapeutics encourages visiting their website at paradigmtherapeutics.com.